ZHAN Qi, LI Yueyue, WANG Xiaojun, CHEN Anni, GU Suli, ZHANG Guoqing. Analysis of application of human albumin after hepatectomy for primary liver cancer[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(5): 463-466. doi: 10.3969/j.issn.1006-0111.2015.05.023
Citation:
|
ZHAN Qi, LI Yueyue, WANG Xiaojun, CHEN Anni, GU Suli, ZHANG Guoqing. Analysis of application of human albumin after hepatectomy for primary liver cancer[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(5): 463-466. doi: 10.3969/j.issn.1006-0111.2015.05.023
|
Analysis of application of human albumin after hepatectomy for primary liver cancer
- Received Date: 2015-02-03
- Rev Recd Date:
2015-07-27
-
Abstract
Objective To assess the use of human albumin (ALB) after hepatectomy in hepatocellular carcinoma patients in our hospital. Methods 150 hospital medical records from June 2012 to June 2013 were analyzed, which used the human serum albumin during the perioperative period of hepatectomy at hepatocellular carcinoma (preoperative Child-Pugh A or B) retrospectively, the rationality of human blood albumin use was evaluated. Results Among the 150 medical records, the total application amount of albumin was 11 212.5 g (897 bottles), the total cost was 527,744 yuan, nearly 20 percent of total drug costs, accounting for nearly 10% of the total cost of hospitalization. By using human serum albumin after surgery, the patients' liver function was significantly improved(P<0.05), there was a positive correlation between the Child-Pugh score and dosage of human albumin (P<0.05). Conclusion The use of human serum albumin was rational during the perioperative period of hepatectomy in hepatocellular carcinoma patients in our hospital, which had achieved the desired therapeutic effect.
-
References
[1]
|
中国抗癌协会肝癌专业委员会,中国抗癌协会临床肿瘤学协作专业委员会,中华医学会肝病学分会肝癌组. 原发性肝癌规范化诊治的专家共识[J].肿瘤,2009,29(4):295-304. |
[2]
|
Vermeulen LC Jr, Ratko TA, Erstad BL,et al.A paradigm for consensus--the University Hospital Consortium Guidelinesfor the use of albumin.nonproteincolloid, and crystalloid solutions[J].Arch Intern Med,1995,155(4):373-379. |
[3]
|
许戈良,荚卫东.肝切除术中肝脏功能的影响因素及其评估[J]. 世界华人消化杂志,2010,18(35):3721-3723. |
[4]
|
毛一雷,桑新亭,杨志英,等.肝脏手术后病人白蛋白临床应用研究[J].中国实用外科杂志,2007,27(8):616-618. |
[5]
|
邓侠兴,沈柏用,吕文杰,等.百特5%及25%人血白蛋白在肝脏、胰腺手术围手术期应用的疗效和安全性[J].中华肝胆外科杂志,2009,15(3):192-195. |
[6]
|
吴 军,仇毓东,朱新华,等.原发性肝癌精准肝切除术后应用羟乙基淀粉的临床研究[J].中国普通外科杂志,2011,20(1):27-31. |
[7]
|
Fan ST, Lo CM, Liu CL, et al. Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths[J]. Ann Surg,1999,229:322-330. |
[8]
|
Johnson M, Mannar R, Wu AV. Correlation between blood loss and inferior vena caval pressure during liver resection[J]. Br J Surg,1998,85:188-190. |
[9]
|
许戈良,荚卫东.肝切除术中肝脏功能的影响因素及其评估[J]. 世界华人消化杂志,2010, 18(35): 3721-3723. |
[10]
|
张 坚,韩启明,玉素甫.重视人血白蛋白的临床应用及管理[J].新疆医学,2008,36:249-253. |
[11]
|
梁 兵,田兆嵩.白蛋白的临床应用[J].中国输血杂志,2008,21(1):68-70. |
-
-
Proportional views
-